Iterum Therapeutics PLC
NASDAQ:ITRM
Iterum Therapeutics PLC
NASDAQ:ITRM
Price:
1.61 USD
0.63%
Market Closed
Updated:
May 10, 2024
Iterum Therapeutics PLC
Research & Development
|
Iterum Therapeutics PLC
Research & Development Peer Comparison
Comparables:
PRGO
JAZZ
AVDL
G
GHRS
COPN
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Research & Development
-$40m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Research & Development
-$122.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
1%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Research & Development
-$911.1m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-18%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Research & Development
-$13.3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
20%
|
CAGR 10-Years
2%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Research & Development
-$29.5m
|
CAGR 3-Years
-343%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Research & Development
-€14.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
2%
|
See Also
What is Iterum Therapeutics PLC's Research & Development?
Research & Development
-40m
USD
-40m
USD
Based on the financial report for Dec 31, 2023, Iterum Therapeutics PLC's Research & Development amounts to -40m USD.
What is Iterum Therapeutics PLC's Research & Development growth rate?
Research & Development CAGR 5Y
10%
10%
Over the last year, the Research & Development growth was -127%. The average annual Research & Development growth rates for Iterum Therapeutics PLC have been -24% over the past three years , 10% over the past five years .
You don't have any saved screeners yet
